Literature DB >> 15342393

Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice.

Inna Serganova1, Michael Doubrovin, Jelena Vider, Vladimir Ponomarev, Suren Soghomonyan, Tatiana Beresten, Ludmila Ageyeva, Alexander Serganov, Shangde Cai, Julius Balatoni, Ronald Blasberg, Juri Gelovani.   

Abstract

Tumor hypoxia is a spatially and temporally heterogeneous phenomenon, which results from several tumor and host tissue-specific processes. To study the dynamics and spatial heterogeneity of hypoxia-inducible factor-1 (HIF-1)-specific transcriptional activity in tumors, we used repetitive noninvasive positron emission tomography (PET) imaging of hypoxia-induced HIF-1 transcriptional activity in tumors in living mice. This approach uses a novel retroviral vector bearing a HIF-1-inducible "sensor" reporter gene (HSV1-tk/GFP fusion) and a constitutively expressed "beacon" reporter gene (DsRed2/XPRT). C6 glioma cells transduced with this multireporter system revealed dose-dependent patterns in temporal dynamics of HIF-1 transcriptional activity induced by either CoCl2 or decreased atmospheric oxygen concentration. Multicellular spheroids of C6 reporter cells developed a hypoxic core when >350 microm in diameter. 18F-2'-fluoro-2'deoxy-1beta-D-arabionofuranosyl-5-ethyl-uracil (FEAU) PET revealed spatial heterogeneity of HIF-1 transcriptional activity in reporter xenografts in mice as a function of size or ischemia-reperfusion injury. With increasing tumor diameter (>3 mm), a marked increase in HIF-1 transcriptional activity was observed in the core regions of tumors. Even a moderate ischemia-reperfusion injury in small C6 tumors caused a rapid induction of HIF-1 transcriptional activity, which persisted for a long time because of the inability of C6 tumors to rapidly compensate acute changes in tumor microcirculation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15342393     DOI: 10.1158/0008-5472.CAN-04-0842

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  58 in total

Review 1.  Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments.

Authors:  Y Waerzeggers; P Monfared; T Viel; A Faust; K Kopka; M Schäfers; B Tavitian; A Winkeler; A Jacobs
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 2.  Human gene therapy and imaging in neurological diseases.

Authors:  Andreas H Jacobs; Alexandra Winkler; Maria G Castro; Pedro Lowenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

Review 3.  Molecular imaging of brain tumors: a bridge between clinical and molecular medicine?

Authors:  B J Schaller; M Modo; M Buchfelder
Journal:  Mol Imaging Biol       Date:  2007 Mar-Apr       Impact factor: 3.488

4.  The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects.

Authors:  David L Schwartz; Garth Powis; Arun Thitai-Kumar; Yi He; James Bankson; Ryan Williams; Robert Lemos; Junghwan Oh; Andrei Volgin; Suren Soghomonyan; Ryuichi Nishii; Mian Alauddin; Uday Mukhopadhay; Zhenghong Peng; William Bornmann; Juri Gelovani
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

5.  Synthesis and in vitro evaluation of 5-[(18)f]fluoroalkyl pyrimidine nucleosides for molecular imaging of herpes simplex virus type 1 thymidine kinase reporter gene expression.

Authors:  Ann-Marie Chacko; Wenchao Qu; Hank F Kung
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

Review 6.  Imaging virus-associated cancer.

Authors:  De-Xue Fu; Catherine A Foss; Sridhar Nimmagadda; Richard F Ambinder; Martin G Pomper
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

7.  5-[18F]Fluoroalkyl pyrimidine nucleosides: probes for positron emission tomography imaging of herpes simplex virus type 1 thymidine kinase gene expression.

Authors:  Ann-Marie Chacko; Eric Blankemeyer; Brian P Lieberman; Wenchao Qu; Hank F Kung
Journal:  Nucl Med Biol       Date:  2009-01       Impact factor: 2.408

8.  An immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer.

Authors:  Hong Song; Karineh Shahverdi; David L Huso; Yuchuan Wang; James J Fox; Robert F Hobbs; Barjor Gimi; Kathleen L Gabrielson; Martin G Pomper; Benjamin M Tsui; Zaver Bhujwalla; R Todd Reilly; George Sgouros
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

9.  Imaging of lymph node micrometastases using an oncolytic herpes virus and [F]FEAU PET.

Authors:  Peter Brader; Kaitlyn Kelly; Sheng Gang; Jatin P Shah; Richard J Wong; Hedvig Hricak; Ronald G Blasberg; Yuman Fong; Ziv Gil
Journal:  PLoS One       Date:  2009-03-10       Impact factor: 3.240

Review 10.  The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients.

Authors:  Muireann T Kelleher; Gilbert Fruhwirth; Gargi Patel; Enyinnaya Ofo; Frederic Festy; Paul R Barber; Simon M Ameer-Beg; Borivoj Vojnovic; Cheryl Gillett; Anthony Coolen; György Kéri; Paul A Ellis; Tony Ng
Journal:  Target Oncol       Date:  2009-09-16       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.